Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

NCT07436858 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)
HER2 Expression
HER2 Gene Mutation

Interventions

DIAGNOSTIC_TEST: PET imaging with ⁸⁹Zr-trastuzumab
DIAGNOSTIC_TEST: Blood sampling for pharmacokinetics

Sponsor

The Netherlands Cancer Institute